Results 161 to 170 of about 23,011 (205)
Some of the next articles are maybe not open access.
Prognostic Values of Soluble CD30 and CD30 Gene Polymorphisms in Heart Transplantation
Transplantation, 2006Pretransplant soluble CD30 (sCD30) is a predictor of kidney graft outcome. Its status as a predictor of heart transplant (HT) outcome has not been established. We have studied this question by assessing sCD30 levels and the number of (CCAT)n repeats of the microsatellite in the CD30 promoter region, which is able alone to repress gene transcription, in
Elisa, Frisaldi +9 more
openaire +2 more sources
CD30 as a Therapeutic Target for Lymphoma
BioDrugs, 2013Hodgkin's lymphoma (HL) and ALK(+) anaplastic large-cell lymphoma (ALCL) have become highly curable due to the success of modern regimens of chemotherapy and radiotherapy. However, up to one-third of the patients experience relapse or do not respond to first-line therapy, and half of them relapse again after secondary therapy with limited options for ...
Schirrmann, Thomas +5 more
openaire +2 more sources
Cytokeratin and CD30 expression in dysgerminoma
Human Pathology, 2006Dysgerminoma is a malignant germ cell tumor of the ovary that shares morphological, immunophenotypic, and genetic features with its testicular counterpart, seminoma. Recent evidence supports the hypothesis that seminoma can differentiate into non-seminomatous germ cell tumor types. The progression of these tumors can be measured by their acquisition of
COSSU ROCCA, Paolo Alessandro +6 more
openaire +3 more sources
Role for CD30 in HIV expression
Immunology Letters, 1996CD30 is a member of the tumor necrosis factor (TNF)-receptor superfamily, whose ligand (CD30L) has been identified on B cells, activated macrophages and a subset of activated T cells. We show here that infection in vitro with human immunodeficiency virus (HIV) of CD4+ T-cell clones generated from HIV-seronegative individuals can enhance the expression ...
ROMAGNANI, SERGIO +9 more
openaire +3 more sources
CD30-Positive Lymphoproliferative Disorders
2018Primary cutaneous CD30-positive lymphoproliferative disorders (CD30+ LPD) encompass lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma (pcALCL), and borderline lesions [1]. CD30+ LPD are the second most common cutaneous T-cell lymphomas (CTCL) after mycosis fungoides (MF) and represent approximately 25% of all CTCL cases [2].
Liana, Nikolaenko +3 more
openaire +2 more sources
CD30+ Lymphomatoid Drug Reactions
The American Journal of Dermatopathology, 2013We report 5 cases of cutaneous CD30+ lymphomatoid drug reactions that occurred shortly after the onset of drug exposure and resolved promptly upon withdrawal of the offending agents. The cases showed protean dermatologic manifestations ranging from diffuse erythema with desquamation to macules, papules, and annular plaques.
Melissa P, Pulitzer +3 more
openaire +2 more sources
CD30-targeted antibody therapy
Current Opinion in Oncology, 2011This article reviews the current knowledge of therapeutic targeting of CD30+ cancers using naked and conjugated monoclonal antibodies.After unsuccessful outcome of early trials using naked and conjugated anti-CD30 antibodies, substantial progress was achieved with the development of the antibody-drug-conjugate brentuximab vedotin.
openaire +2 more sources
Expression of CD30 and CD30 ligand (CD30L) in the neoplastic lesions of the thyroid.
1999(abstract 64) - ISSN:
TROVATO, Maria Concetta +10 more
openaire +1 more source